Form 4: Achieve Life Sciences Director Nancy Phelan Granted 31,500 Stock Options

Achieve Life Sciences, Inc. Director Nancy R. Phelan was granted 31,500 stock options with an exercise price of $3.83, vesting by June 2026.

Summary

• Nancy R. Phelan, a Director of ACHIEVE LIFE SCIENCES, INC. (ACHV), was granted 31,500 stock options.
• The transaction date for this grant was June 6, 2025.
• Each stock option has an exercise price of $3.83.
• The options are for Common Stock, with each option representing the right to buy one share.
• These options will vest 100% on the earlier of June 6, 2026, or the date immediately prior to the Issuer's 2026 annual meeting of stockholders.
• The expiration date for these stock options is June 6, 2035.
• Following this transaction, Nancy R. Phelan directly beneficially owns 31,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a standard practice of aligning director interests with shareholders through equity compensation. It is a routine disclosure and not indicative of significant operational or financial changes, hence not extremely positive.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Negatives

• No direct negatives are indicated in this Form 4 filing, as it primarily reports a routine equity compensation event.

Risks

• This document does not detail specific risks to the company's operations or financial health; it is a disclosure of insider stock ownership changes.

Future Outlook

The vesting schedule for the granted options, set for June 2026 or earlier, indicates a future alignment of the director's interests with the company's long-term performance and shareholder value creation.

Management Comments

• The filing itself is a report of a transaction by a member of management (a director), reflecting a decision by the company's compensation committee or board to grant equity as part of compensation.

Industry Context

The granting of stock options to directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to incentivize long-term commitment and performance aligned with shareholder interests.

Comparison to Industry Standards

• Granting stock options to directors is a standard component of executive and board compensation packages across various industries, including biotech companies like Achieve Life Sciences.
• The specific number of options (31,500) and the exercise price ($3.83) would typically be benchmarked against peer companies of similar market capitalization, stage of development, and industry sector, though this document does not provide such comparative data.
• The vesting schedule (100% on the earlier of one year or the next annual meeting) is a common structure for director equity grants, aiming to retain directors and align their interests over a reasonable period.

Corporate Governance

Related Party Transactions

• The grant of stock options to Nancy R. Phelan, a Director of Achieve Life Sciences, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders, potentially leading to better long-term decision-making and value creation.
• Employees: While not directly impacting general employees, such compensation practices can set a precedent for equity incentives across the organization.
• Management: This transaction is part of the overall compensation structure for the company's leadership, including its board of directors.

Next Steps

• The options will vest on the earlier of June 6, 2026, or the date immediately prior to the Issuer's 2026 annual meeting of stockholders, at which point they become exercisable.
• The director may choose to exercise these options at any time after vesting and before the expiration date of June 6, 2035.

Key Dates

Keywords

Achieve Life Sciences, ACHV, Stock Options, Insider Transaction, Director Compensation, Equity Grant, Form 4, Beneficial Ownership